Sandoz, the generics-focused unit of Novartis, agrees to pay a $450 million settlement to resolve antitrust allegations brought by 43 U.S. states and related parties, according to reporting by multiple outlets. The claims relate to alleged anticompetitive conduct in connection with certain generic drug products. Terms of the settlement are structured to resolve the state attorneys general’s case and related legal matters, with the amount covering potential liabilities claimed under U.S. antitrust laws.
The outlets describe the settlement as a negotiated resolution rather than an adjudicated finding in favor of either side. Details of how funds will be distributed among participating states and whether other litigation remains are not described in the provided excerpts. The agreement indicates that Sandoz addresses the states’ allegations through a monetary payment and closure of that matter, while the broader legal context—such as any separate federal claims or other proceedings—is not covered in the supplied material.
The settlement is presented as a significant monetary resolution involving a large coalition of state governments.
